C-terminal tetrapeptides inhibit aβ42-induced neurotoxicity primarily through specific interaction at the N-Terminus of Aβ42

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8451-8460

  Li, Huiyuan ^a   Du, Zhenming ^c   Lopes, Dahabada H J ^a   Fradinger, Erica A ^a,d   Wang, Chunyu ^a   Bitan, Gal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^d WHITTIER COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TETRAPEPTIDE; TYROSINE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHIRALITY; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HYDROPHOBICITY; INHIBITION KINETICS; MOLECULAR INTERACTION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE; PROTEIN STRUCTURE; STATIC ELECTRICITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; BINDING SITES; CELL SURVIVAL; FLUORESCENCE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PC12 CELLS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 84055176288     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200982p     Document Type: Article

References (56)

1. Walsh, D. M.; Selkoe, D. J. Aβ oligomers - a decade of discovery. J. Neurochem. 2007, 101, 1172-1184.
2. Kirkitadze, M. D.; Bitan, G.; Teplow, D. B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 2002, 69, 567-577.
3. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
4. Ferreira, S. T.; Vieira, M. N.; De Felice, F. G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 2007, 59, 332-345.
5. Dahlgren, K. N.; Manelli, A M.; Stine, W. B. Jr.; Baker, L. K.; Krafft, G A.; LaDu, M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277, 32046-32053.
6. Bitan, G.; Kirkitadze, M. D.; Lomakin, A.; Vollers, S. S.; Benedek, G. B.; Teplow, D. B. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA. 2003, 100, 330-335.
7. Bernstein, S. L.; Dupuis, N. F.; Lazo, N. D.; Wyttenbach, T.; Condron, M. M.; Bitan, G; Teplow, D. B.; Shea, J.-E.; Ruotolo, B. T.; Robinson, C. V.; Bowers, M. T. Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nature Chem. 2009, 1, 326-331.
8. Bitan, G.; Vollers, S. S.; Teplow, D. B. Elucidation of primary structure elements controlling early amyloid β-protein oligomerization. J. Biol. Chem. 2003, 278, 34882-34889.
9. Lazo, N. D.; Grant, M. A.; Condron, M. C.; Rigby, A C.; Teplow, D. B. On the nucleation of amyloid β-protein monomer folding. Protein Sci. 2005, 14, 1581-1596.
10. Urbanc, B.; Cruz, L.; Yun, S.; Buldyrev, S. V.; Bitan, G.; Teplow, D. B.; Stanley, H. E. In silico study of amyloid β-protein folding and oligomerization. Proc. Natl. Acad. Sci. U.SA. 2004, 101, 17345-17350.
11. Tjernberg, L. O.; Näslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A. R; Thyberg, J.; Terenius, L.; Nordstedt, C. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271, 8545-8548.
12. Soto, C.; Kindy, M. S.; Baumann, M.; Frangione, B. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 1996, 226, 672-680.
13. Lowe, T. L.; Strzelec, A.; Kiessling, L. L.; Murphy, R M. Structure-function relationships for inhibitors of β-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 2001, 40, 7882-7889.
14. Findeis, M. A.; Musso, G M.; Arico-Muendel, C. C.; Benjamin, H. W.; Hundal, A. M.; Lee, J. J.; Chin, J.; Kelley, M.; Wakefield, J.; Hayward, N. J.; Molineaux, S. M. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochemistry 1999, 38, 6791-6800.
15. Hughes, E.; Burke, R M.; Doig, A. J. Inhibition of toxicity in the β-amyloid peptide fragment β-(25-35) using N-methylated derivatives - a general strategy to prevent amyloid formation. J. Biol. Chem. 2000, 275, 25109-25115.
16. Gordon, D. J.; Sciarretta, K. L.; Meredith, S. C. Inhibition of β-amyloid(40) fibrillogenesis and disassembly of β-amyloid(40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 2001, 40, 8237-8245.
17. Zhang, S.; Iwata, K.; Lachenmann, M. J.; Peng, J. W.; Li, S.; Stimson, E. R; Lu, Y.; Felix, A. M.; Maggio, J. E.; Lee, J. P. The Alzheimer's peptide Aβ adopts a collapsed coil structure in water. J. Struct. Biol. 2000, 130, 130-141.
18. 42-induced toxicity. J. Am. Chem. Soc. 2011, 133, 4348-4358.
19. Hetenyi, C.; Szabo, Z; Klement, T.; Datki, Z; Kortvelyesi, T.; Zarandi, M.; Penke, B. Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease. Biochem. Biophys. Res. Commun. 2002, 292, 931-936.
20. Szegedi, V.; Fülöp, L.; Farkas, T.; Rozsa, E.; Robotka, H.; Kis, Z; Penke, Z; Horvath, S.; Molnar, Z; Datki, Z; Soos, K.; Toldi, J.; Budai, D.; Zarandi, M.; Penke, B. Pentapeptides derived from Aβ1-42 protect neurons from the modulatory effect of Aβ fibrils - an in vitro and in vivo electrophysiological study. Neurobiol Dis. 2005, 18, 499-508.
21. Pratim Bose, P.; Chatterjee, U.; Nerelius, C.; Govender, T.; Norstrom, T.; Gogoll, A.; Sandegren, A.; Gothelid, E; Johansson, J.; Arvidsson, P. I. Poly-N-methylated amyloid β-peptide (Aβ) C-terminal fragments reduce Aβ toxicity in vitro and in Drosophila melanogaster. J. Med. Chem. 2009, 52, 8002-8009.
22. Rahimi, A. F.; Shanmugam, A.; Bitan, G Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr. Alzheimer Res. 2008, 5, 319-341.
23. Fradinger, E. A.; Monien, B. H.; Urbanc, B.; Lomakin, A.; Tan, M.; Li, H.; Spring, S. M.; Condron, M. M.; Cruz, L.; Xie, C. W.; Benedek, G B.; Bitan, G C-Terminal peptides coassemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proc. Natl. Acad. Sci. U.SA. 2008, 105, 14175-14180.
24. Li, H; Monien, B. H.; Lomakin, A.; Zemel, R; Fradinger, E. A.; Tan, M.; Spring, S. M.; Urbanc, B.; Xie, C. W.; Benedek, G. B.; Bitan, G Mechanistic investigation of the inhibition of Aβ42 assembly and neurotoxicity by Aβ42 C-terminal fragments. Biochemistry 2010, 49, 6358-6364.
25. Urbanc, B.; Betnel, M.; Cruz, L.; Li, H.; Fradinger, E. A.; Monien, B. H.; Bitan, G Structural basis for Aβ(1-42) toxicity inhibition by Aβ C-terminal fragments: discrete molecular dynamics study. J. Mol. Biol. 2011, 410, 316-328.
26. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
27. Veber, D. F.; Johnson, S. R; Cheng, H. Y.; Smith, B. R; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
28. Bertrand, R; Solary, E; O'Connor, P.; Kohn, K. W.; Pommier, Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res. 1994,211,314-321.
29. Arispe, N; Diaz, J. C.; Simakova, O. Aβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers. Biochim. Biophys. Acta 2007, 1768, 1952-1965.
30. Sokolov, Y.; Kozak, J. A.; Kayed, R; Chanturiya, A.; Glabe, C.; Hall, J. E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 2006, 128, 637-647.
31. Fringeli, U. P.; Fringeli, M. Pore formation in lipid membranes by alamethicin. Proc. Natl. Acad. Sci. U.SA. 1979, 76, 3852-3856.
32. Auluck, P. K.; Caraveo, G.; Lindquist, S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26, 211-233.
33. Condron, M. M.; Monien, B. H.; Bitan, G Synthesis and purification of highly hydrophobic peptides derived from the C-terminus of amyloid β-protein. Open Biotechnol. J. 2008, 2, 87-93.
34. Maji, S. K.; Amsden, J. J.; Rothschild, K J.; Condron, M. M.; Teplow, D. B. Conformational dynamics of amyloid β-protein assembly probed using intrinsic fluorescence. Biochemistry 2005, 44, 13365-13376.
35. Maji, S. K.; Ogorzalek Loo, R R; Inayathullah, M.; Spring, S. M.; Vollers, S. S.; Condron, M. M.; Bitan, G; Loo, J. A.; Teplow, D. B. Amino acid position-specific contributions to amyloid β-protein oligomerization. J. Biol. Chem. 2009, 284, 23580-23591.
36. Lakowicz, J. R Principles of Fluorescence Spectroscopy; 2nd ed.; Kluwer Academic/Plenum Publishers: New York, 1999; p 698.
37. Zagorski, M. G; Yang, J.; Shao, H; Ma, K.; Zeng, H.; Hong, A. Methodological and chemical factors affecting amyloid β peptide amyloidogenicity. Methods Enzymol. 1999, 309, 189-204.
38. Stine, W. B. Jr.; Dahlgren, K N; Krafft, G A.; LaDu, M. J. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278, 11612-11622.
39. Yan, Y.; Wang, C. Aβ42 is more rigid than Aβ40 at the C terminus: implications for Aβ aggregation and toxicity. J. Mol. Biol. 2006, 364, 853-862.
40. Gessel, M. M.; Wu, C.; Li, H; Bitan, G.; Shea, J. E.; Bowers, M. T. Unpublished results.
41. Janssen, J. C.; Beck, J. A.; Campbell, T. A.; Dickinson, A.; Fox, N. C.; Harvey, R J.; Houlden, H; Rossor, M. N; Collinge, J. Early onset familial Alzheimer's disease-mutation frequency in 31 families. Neurology 2003, 60, 235-239.
42. Wakutani, Y.; Watanabe, K.; Adachi, Y; Wada-Isoe, K.; Urakami, K.; Ninomiya, H; Saido, T. C.; Hashimoto, T.; Iwatsubo, T.; Nakashima, K Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J. Neurol. Neurosurg Psychiatry 2004, 75, 1039-1042.
43. Ono, K.; Condron, M. M.; Teplow, D. B. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. J. Biol. Chem. 2010, 285, 23186-23197.
44. Qahwash, I.; Weiland, K L.; Lu, Y. F.; Sarver, R W.; Kletzien, R F.; Yan, R Q. Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. J. Biol. Chem. 2003, 278, 23187-23195.
45. He, W. L.; Barrow, C. J. The Aβ 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β-sheet forming and aggregation propensities in vitro than full-length Aβ. Biochemistry 1999, 38, 10871-10877.
46. Schilling, S.; Lauber, T.; Schaupp, M.; Manhart, S.; Scheel, E.; Bohm, G; Demuth, H. U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45, 12393-12399.
47. Russo, C.; Violani, E.; Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G; Benatti, U; D'Arrigo, C.; Patrone, E.; Carlo, P.; Schettini, G Pyroglutamate-modified amyloid β-peptides- Aβ N3(pE)-strongly affect cultured neuron and astrocyte survival. J. Neurochem. 2002, 82, 1480-1489.
48. Wirths, O.; Breyhan, H; Cynis, H; Schilling, S.; Demuth, H. U; Bayer, T. A Intraneuronal pyroglutamate-Aβ 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118, 487-496.
49. Hwang, C. S.; Shemorry, A.; Varshavsky, A N-Terminal acetylation of cellular proteins creates specific degradation signals. Science 2010, 327, 973-977.
50. Urbanc, B.; Betnel, M.; Cruz, L.; Bitan, G; Teplow, D. B. Elucidation of amyloid β-protein oligomerization mechanisms: discrete molecular dynamics study. J. Am. Chem. Soc. 2010, 132, 4266-4280.
51. Zhao, W. Q.; Toolan, D.; Hepler, R W.; Wolfe, A L.; Yu, Y; Price, E.; Uebele, V. N; Schachter, J. B.; Reynolds, I. J.; Renger, J. J.; McCampbell, A.; Ray, W. J. High throughput monitoring of amyloid-β42 assembly into soluble oligomers achieved by sensitive conformation state-dependent immunoassays. J. Alzheimer's Dis. 2011,25,655-669.
52. Chan, W. C.; White, P. D. Fmoc Solid-Phase Peptide Synthesis: A Practical Approach; Oxford University Press: New York, 2000; p xxiv, 346.
53. Gude, M.; Ryf, J.; White, P. D. An accurate method for the quantitiation of Fmoc-derivatized solid phase support. Lett. Pept. Sci. 2002, 9, 203-206.
54. Varady, L.; Rajur, S. B.; Nicewonger, R. B.; Guo, M.; Ditto, L. Fast and quantitative high-performance liquid chromatography method for the determination of 9-fluorenylmethoxycarbonyl release from solid-phase synthesis resins. J. Chromatogr., A 2000, 869, 171-179.
55. Rahimi, F.; Maiti, P.; Bitan, G. Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. J. Vis. Exp. 2009, http://www.jove.com/index/details.stp?id=1071.
56. Li, H.; Monien, B. H.; Fradinger, E. A.; Urbanc, B.; Bitan, G. Biophysical characterization of Aβ42 C-terminal fragments: inhibitors of Aβ42 neurotoxicity. Biochemistry 2010, 49, 1259-1267.